FDA OKs aducanumab for Alzheimer's, turning controversial Biogen drug into a megablockbuster

Jason Mast

Editor

The FDA has approved the Biogen drug aducanumab for Alzheimer’s, a stunning decision that caps nearly two years of controversy and hands the large biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA OKs aducanumab for Alzheimer's, turning controversial Biogen drug into a megablockbuster

Jason Mast

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

FDA OKs ad­u­canum­ab for Alzheimer's, turn­ing con­tro­ver­sial Bio­gen drug in­to a megablock­buster

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

FDA OKs aducanumab for Alzheimer's, turning controversial Biogen drug into a megablockbuster